OpGen (NASDAQ:OPGN) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
OpGen (NASDAQ:OPGN) last announced its earnings results on Tuesday, May 14th. The medical research company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08). OpGen had a negative return on equity of 313.92% and a negative net margin of 454.23%. The business had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $1.20 million. On average, analysts expect OpGen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ OPGN traded down $0.01 during midday trading on Wednesday, reaching $0.34. The company’s stock had a trading volume of 400 shares, compared to its average volume of 143,816. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.37 and a quick ratio of 1.27. The firm has a market cap of $6.49 million, a PE ratio of -0.16 and a beta of 0.84. The firm has a 50 day moving average price of $0.38. OpGen has a 12-month low of $0.32 and a 12-month high of $2.41.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.